Citations

Clear

3030 citation(s) found for "Susan, M".

Physiotherapy management of fibromyalgia syndrome: a survey of practice in Northern Ireland
McVeigh, Joseph G. , Archer, Susan, Hurley, Deirdre A. , Basford, Jeffrey R. , Baxter, David

Mayo Clinic

International Journal of Therapy and Rehabilitation | May 23, 2014 | Volume: 11 | Issue: 2 | Pages: 71-78

10.12968/ijtr.2004.11.2.13393 Get It

The aim of this study was to identify the physiotherapeutic management of patients with fibromyalgia syndrome (FMS) in Northern Ireland. A postal questionnaire was distributed to physiotherapists working in outpatient settings in this region (n = 106). A response rate of 71% (n = 75) was achieved. Patients with FMS featured in the caseloads of all respondents. The most important reported goal of treatment was to ‘increase daily function’ (n = 24; 32%). Exercise (n = 44; 58.7%) and hydrotherapy (n = 12; 16.0%) were the most common treatment approaches. A total of 45.3% (n = 34) of respondents stated that they did not believe they could adequately assess patients with FMS and 41.3% (n = 31) reported that they had no training in the management of FMS. Private practitioners were significantly (P = 0.05) more likely to believe that physiotherapy was beneficial for patients with FMS than their NHS counterparts. In conclusion, physiotherapy treatments for patients with FMS in Northern Ireland are consistent with current evidence. However, practice varies and physiotherapists are uncomfortable with their level of training in FMS.
A survey of community paramedicine course offerings and planned offerings
Raynovich, William, Wilcox, Michael R, Wingrove, Gary , Robinson-Montera, Anne, Long, Susan , Weber, Michael

Mayo Clinic

International Paramedic Practice | May 23, 2014 | Volume: 4 | Issue: 1 | Pages: 19-24

10.12968/ippr.2014.4.1.19 Get It

Introduction: This paper reports on the results of a survey that was sent to every recipient of a standardised Community Paramedic™ (CP) curriculum. The survey was sent out to 223 post-secondary educators and Government officials. Out of 223 total surveys, 68 (30.49%) responses were received. Forty-seven of the 68 responses (69.11%) answered the question: ‘When are you planning on giving a community paramedic course?’; 35 of the 47 respondents (74.46%) indicated that their institution had already conducted a CP course, was currently conducting a CP course, or are planning on conducting a CP course within the next five years; of the additional 12 programmes (25.53%), 6 (13.0%) were waiting for state approval, and the other 6 (13.0%) were unknown as to when they would be offering a course. Conclusions: At the time of the survey, many CP courses were in planning stages by programmes that had received the standardised CP curriculum, both in the US and internationally. It appears that the CP curriculum that has been disseminated internationally has been broadly accepted and will be widely utilised.
Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study
Grothey, Axel, Flick, E. Dawn, Cohn, Allen Lee, Bekaii‐Saab, Tanios , Bendell, Johanna C. , Kozloff, Mark, Roach, Nancy, Mun, Yong, Fish, Susan, Hurwitz, Herbert I. , Bekaii-Saab, Tanios S

Mayo Clinic

Pharmacoepidemiology and Drug Safety | May 16, 2014 | Volume: 23 | Issue: 7 | Pages: 726-734

10.1002/pds.3633 | PMID 24830357 Get It

ABSTRACTPurposeThis analysis from Avastin® Registries: Investigation of Effectiveness and Safety (ARIES) examined the association between exposure to bevacizumab after disease progression (PD) and postprogression survival (PPS) in bevacizumab‐exposed metastatic colorectal cancer (mCRC) through the application of time‐dependent and time‐fixed analytical methods.MethodsPatients with mCRC who were treated with first‐line bevacizumab and who survived first PD (PD1) were included. A time‐dependent Cox regression model was fitted to assess the effect of cumulative bevacizumab exposure on PPS, while controlling for potential confounders. In addition to support findings from previous studies, a modified intent‐to‐treat (mITT) analysis compared PPS in patients who received bevacizumab beyond disease progression (BBP) with those who did not (No‐BBP).ResultsOf 1550 patients, 1199 survived PD1 and had a median PPS of 13.4 months. Cumulative bevacizumab exposure was associated with improved PPS (p = 0.0040). After adjusting for confounders, the hazard ratios (HRs) for PPS decreased, on average, by 1.2% (range, 1.1–1.3%) with each additional dose of bevacizumab. In the mITT analysis, the median PPS for BBP (n = 438) was 14.4 months vs 10.6 months with for No‐BBP (n = 667). BBP was found to be independently associated with longer PPS in a multivariable Cox regression analysis (HR, 0.84; 95% confidence interval, 0.73–0.97). Protocol‐specified adverse events suspected to be associated with bevacizumab occurred in 13.0% of patients with BBP.ConclusionThis analysis supports the observation that bevacizumab exposure after PD1 is associated with longer PPS in mCRC. Copyright © 2014 John Wiley & Sons, Ltd.
Integration of A Stress Management and Resiliency Training (SMART) Program in a Nurse Residency Program: A Feasibility Study
Sood, Amit , Morin, Karen H. , Cutshall, Susan, Douglas, Kristin Vickers, Chesak, Sherry S. , Cutshall, Susanne M. , Ridgeway, Jennifer L.

Mayo Clinic

The Journal of Alternative and Complementary Medicine | May 7, 2014 | Volume: 20 | Issue: 5 | Pages: A101-A101

10.1089/acm.2014.5267.abstract Get It

Predictors of Chronic Obstructive Pulmonary Disease Exacerbation Reduction in Response to Daily Azithromycin Therapy
Tayob, Nabihah , Murray, Susan , Washko, George R. , Scanlon, Paul D., Casaburi, Richard , Connett, John E. , Lazarus, Stephen C. , Albert, Richard , Woodruff, Prescott G. , Han, MeiLan King , Dransfield, Mark T. , Criner, Gerard J. , Martínez, Fernando J.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | April 29, 2014 | Volume: 189 | Issue: 12 | Pages: 1503-1508

10.1164/rccm.201402-0207oc | PMID 24779680 Get It

Abstract Rationale Daily azithromycin decreases acute exacerbations of chronic obstructive pulmonary disease (AECOPD), but long-term side effects are unknown. Objectives To identify the types of exacerbations most likely to be reduced and clinical subgroups most likely to benefit from azithromycin, 250 mg daily, added to usual care. Methods Enrollment criteria included irreversible airflow limitation and AECOPD requiring corticosteroids, emergency department visit, or hospitalization in the prior year or use of supplemental oxygen. Recurrent events and cumulative incidence analyses compared treatment received for AECOPD by randomization group, stratified by subgroups of interest. Cox proportional hazards models estimated treatment effects in subgroups adjusted for age, sex, smoking status, FEV1% predicted, concomitant COPD medications, and oxygen use. Measurements and Main Results Azithromycin was most effective in reducing AECOPD requiring both antibiotic and steroid treatment (n = 1,113; cumulative incidence analysis, P = 0.0002; recurrent events analysis, P = 0.002). No difference in treatment response by sex (P = 0.75), presence of chronic bronchitis (P = 0.19), concomitant inhaled therapy (P = 0.29), or supplemental oxygen use (P = 0.23) was observed. Older age and milder Global Initiative for Chronic Obstructive Lung Disease stage were associated with better treatment response (P = 0.02 and 0.04, respectively). A significant interaction between treatment and current smoking was seen (P = 0.03) and azithromycin did not reduce exacerbations in current smokers (hazard ratio, 0.99; 95% confidence interval, 0.71–1.38; P = 0.95). Conclusions Azithromycin is most effective in preventing AECOPD requiring both antibiotic and steroid treatment. Adjusting for confounders, we saw no difference in efficacy by sex, history of chronic bronchitis, oxygen use, or concomitant COPD therapy. Greater efficacy was seen in older patients and milder Global Initiative for Chronic Obstructive Lung Disease stages. We found little evidence of treatment effect among current smokers. Clinical trial registered with www.clinicaltrials.gov (NCT0011986 and NCT00325897).
Evidence that the Lung Adenocarcinoma EML4-ALK Fusion Gene Is not Caused by Exposure to Secondhand Tobacco Smoke During Childhood
Wang, Yi , Jen, Jin , Yi, Eunhee S. , Olivo‐Marston, Susan , Harris, Curtis C. , Ryan, Bríd M. , Yang, Ping

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | April 24, 2014 | Volume: 23 | Issue: 7 | Pages: 1432-1434

10.1158/1055-9965.epi-14-0224 | PMID 24755712 Get It

Abstract Background: The EML4-ALK fusion gene is more frequently found in younger, never smoking patients with lung cancer. Meanwhile, never smokers exposed to secondhand tobacco smoke (SHS) during childhood are diagnosed at a younger age compared with never smoking patients with lung cancer who are not exposed. We, therefore, hypothesized that SHS, which can induce DNA damage, is associated with the EML4-ALK fusion gene. Methods: We compared the frequency of the EML4-ALK fusion gene among 197 never smoker patients with lung cancer with and without a history of exposure to SHS during childhood at Mayo Clinic. Results: The EML4-ALK fusion gene was detected in 33% of cases from never smokers with a history of SHS exposure during childhood, whereas 47% of never smoking lung cancer cases without a history of childhood SHS exposure tested positive for the fusion gene. Conclusions: The EML4-ALK fusion gene is not enriched in tumors from individuals exposed to SHS during childhood. Impact: These data suggest that childhood exposure to SHS is not a significant etiologic cause of the EML4-ALK fusion gene in lung cancer. Cancer Epidemiol Biomarkers Prev; 23(7); 1432–4. ©2014 AACR.
Compatibility of Electroanatomical Mapping Systems with a Concurrent Percutaneous Axial Flow Ventricular Assist Device
Vaidya, Vaibhav R. , Madhavan, Malini , Noheria, Amit , Shahid, Mohammed , Walters, Jacob, Ladewig, Dorothy J., Mikell, Susan B. , Johnson, Susan B., Suddendorf, Scott H., Asirvatham, Samuel J. , DeSimone, Christopher V. , Asirvatham, Samuel J

Mayo Clinic

Journal of Cardiovascular Electrophysiology | April 24, 2014 | Volume: 25 | Issue: 7 | Pages: 781-786

10.1111/jce.12437 | PMID 24758340 Get It

Electromagnetic Interference with Ventricular Assist DeviceBackgroundHemodynamic instability hinders activation and entrainment mapping during ventricular tachycardia ablation. The Impella 2.5 microaxial flow device (MFD; Abiomed Inc., Danvers, MA, USA) is used to prevent hemodynamic instability during electrophysiologic study. However, electromagnetic interference (EMI) generated by this device can preclude accurate electroanatomic mapping.MethodsImpella was placed in the left ventricle of 7 canines for circulatory support. Electroanatomic mapping during sinus rhythm, ventricular pacing, and ventricular fibrillation (VF) was performed using magnet‐ (CARTO3, Biosense Webster Inc., Diamond Bar, CA, USA) and impedance‐ (EnSite Velocity System/EnSite NavX, St. Jude Medical Inc., St. Paul, MN, USA) based systems. Distance from device to points with severe EMI precluding acquisition was compared to points with mild/no EMI. Two methods were used to reduce EMI: (1) titration of MFD performance, and (2) impedance‐only mapping combined with manual annotation of activation.ResultsSevere EMI did not occur during impedance‐based mapping. Severe EMI was observed using CARTO3 at 9.4% of all points attempted at maximum performance level (P8) of device. Severe EMI occurred at points closer to device (40.1 ± 16.8 mm) versus (55.5 ± 20.0 mm) for mild/no EMI, P < 0.0001. Severe EMI using CARTO3 was resolved by either (1) reduction of performance from P8 to P6 or (2) impedance‐only mapping with manual annotation.ConclusionConcurrent use of MFD caused EMI to prevent acquisition of points with magnet‐based mapping. Predictors for EMI were distance from device and performance level. Temporary reductions to P6 or impedance‐only mapping are 2 methods to resolve EMI.
Quality and Safety of Minimally Invasive Surgery: Past, Present, and Future
LaGrange, Chad A. , Hallbeck, Ms, McCrory, Bernadette , Hallbeck, M. Susan

Mayo Clinic

Biomedical Engineering and Computational Biology | April 21, 2014 | Volume: 6 | Issue: No issue available | Pages: No page available

10.4137/becb.s10967 | PMID 25288906 Get It

Adverse events because of medical errors are a leading cause of death in the United States (US) exceeding the mortality rates of motor vehicle accidents, breast cancer, and AIDS. Improvements can and should be made to reduce the rates of preventable surgical errors because they account for nearly half of all adverse events within hospitals. Although minimally invasive surgery (MIS) has proven patient benefits such as reduced postoperative pain and hospital stay, its operative environment imposes substantial physical and cognitive strain on the surgeon increasing the risk of error. To mitigate errors and protect patients, a multidisciplinary approach is needed to improve MIS. Clinical human factors, and biomedical engineering principles and methodologies can be used to develop and assess laparoscopic surgery instrumentation, practices, and procedures. First, the foundational understanding and the imperative to transform health care into a high-quality and safe system is discussed. Next, a generalized perspective is presented on the impact of the design and redesign of surgical technologies and processes on human performance. Finally, the future of this field and the research needed to further improve the quality and safety of MIS is discussed.
Maturation Versus Death of Developing Double-Positive Thymocytes Reflects Competing Effects on Bcl-2 Expression and Can Be Regulated by the Intensity of CD28 Costimulation
McKean, D J, Huntoon, Catherine J., Bell, Michael P., Tai, Xuguang , Sharrow, Susan O., Hedin, Karen E. , Conley, Abigail, Singer, Alfred

Mayo Clinic

The Journal of Immunology | April 20, 2014 | Volume: 166 | Issue: 5 | Pages: 3468-3475

10.4049/jimmunol.166.5.3468 | PMID 11207305 Get It

Abstract Immature double-positive (DP) thymocytes mature into CD4+CD8− cells in response to coengagement of TCR with any of a variety of cell surface “coinducer” receptors, including CD2. In contrast, DP thymocytes are signaled to undergo apoptosis by coengagement of TCR with CD28 costimulatory receptors, but the molecular basis for DP thymocyte apoptosis by TCR plus CD28 coengagement is not known. In the present study, we report that TCR plus CD28 coengagement does not invariably induce DP thymocyte apoptosis but, depending on the intensity of CD28 costimulation, can induce DP thymocyte maturation. We demonstrate that distinct but interacting signal transduction pathways mediate DP thymocyte maturation signals and DP thymocyte apoptotic signals. Specifically, DP maturation signals are transduced by the extracellular signal-related kinase (ERK)/mitogen-activated protein kinase (MAPK) pathway and up-regulate expression of the antiapoptotic protein Bcl-2. In contrast, the apoptotic response stimulated by CD28 costimulatory signals is mediated by ERK/MAPK-independent pathways. Importantly, when TCR-activated thymocytes are simultaneously coengaged by both CD28 and CD2 receptors, CD28 signals can inhibit ERK/MAPK-dependent Bcl-2 protein up-regulation. Thus, there is cross-talk between the signal transduction pathways that transduce apoptotic and maturation responses, enabling CD28-initiated signal transduction pathways to both stimulate DP thymocyte apoptosis and also negatively regulate maturation responses initiated by TCR plus CD2 coengagement.
Augmentation of T Cell Levels and Responses Induced by Androgen Deprivation
Roden, Anja C. , Moser, Michael T. , Tri, Samuel D., Mercader, Maria, Kuntz, Susan M., Hurwitz, Arthur A., McKean, D J, Leibovich, Bradley C. , Allison, James P. , Kwon, Eugene D., Dong, Haidong , Celis, Esteban

Mayo Clinic

The Journal of Immunology | April 20, 2014 | Volume: 173 | Issue: 10 | Pages: 6098-6108

10.4049/jimmunol.173.10.6098 | PMID 15528346 Get It

Abstract Androgen has been implicated as a negative regulator of host immune function and a factor contributing to the gender dimorphism of autoimmunity. Conversely, androgen deprivation has been suggested to potentiate male host immunity. Studies have shown that removal of androgen in postpubertal male mice produces an increase in size and cellularity of primary and peripheral lymphoid organs, and enhances a variety of immune responses. Yet, few details are known about the effect of androgen removal on T cell-mediated immunity. In this study, we demonstrate two pronounced and independent alterations in T cell immunity that occur in response to androgen deprivation, provided by castration, in postpubertal male mice. First, we show that levels of T cells in peripheral lymphoid tissues of mice are increased by androgen deprivation. Second, T cells from these mice transiently proliferate more vigorously to TCR- and CD28-mediated costimulation as well as to Ag-specific activation. In addition, androgen deprivation accelerates normalization of host T and B cell levels following chemotherapy-induced lymphocyte depletion. Such alterations induced by androgen deprivation may have implications for enhancing immune responses to immunotherapy and for accelerating the recovery of the immune system following chemotherapy.